Review Article

The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta-analysis

Tannaz Jamialahmadi,1,2 Željko Reiner,3 Mona Alidadi,1 Matthew Kroh,4 Wael Almahmeed,5 Massimiliano Ruscica,6 Cesare Sirtori,6 Manfredi Rizzo,7 Raul D. Santos,8 and Amirhossein Sahebkar,9

1Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3University Hospital Centre Zagreb, Department of Internal Medicine, Zagreb, Croatia
4Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio, USA
5Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
6Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy
7Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy
8Lipid Clinic Heart Institute (Incor), University of São Paulo, Medical School Hospital, São Paulo, Brazil
9Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
10Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Amirhossein Sahebkar; amir_saheb2000@yahoo.com

Received 6 November 2021; Revised 8 March 2022; Accepted 1 August 2022; Published 17 August 2022

Academic Editor: Syed Sameer Aga

Copyright © 2022 Tannaz Jamialahmadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Obesity, especially severe obesity, is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality. Obesity is a widespread disease on a global scale and a major public health issue [2]. The use of bariatric surgical procedures has increased steadily over the past decades because these procedures are durable and effective weight loss therapy for patients with severe obesity and weight-related comorbidities. Elevated plasma levels of lipoprotein (a) (Lp(a)) are causally associated with ASCVD. The aim of this meta-analysis was to analyze whether bariatric surgery is associated with Lp(a) concentrations. A literature search in PubMed, Scopus, Embase, and Web of Science was performed from inception to May 1st, 2021. A random-effects model and the generic inverse variance weighting method were used to compensate for the heterogeneity of studies in terms of study design, treatment duration, and the characteristics of the studied populations. A random-effects metaregression model was used to explore the association with an estimated effect size. Evaluation of funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests were used to assess the presence of publication bias in the meta-analysis. Results. Meta-analysis of 13 studies including 1551 patients showed a significant decrease of circulating Lp(a) after bariatric surgery (SMD: -0.438, 95% CI: -0.702, -0.174, $p < 0.001$, $I^2$: 94.05%). The results of the metaregression did not indicate any significant association between the changes in Lp(a) and duration of follow-up after surgery, reduction in body mass index, or baseline Lp(a) concentration. The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis. Conclusion. Bariatric surgery significantly decreases circulating Lp(a) concentrations. This decrease may have a positive effect on ASCVD in obese patients.

1. Introduction

It is well known that obesity, especially severe obesity, is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality [1]. Obesity is a widespread disease on a global scale and a major public health issue [2]. The use of bariatric surgical procedures has increased steadily over the past decades because these...
Weight loss has benefited ASCVD, cardiovascular events, and total mortality. The most widely performed bariatric procedures are sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), laparoscopic adjustable gastric band (LAGB), biliopancreatic diversion/duodenal switch (BPD/DS), and one anastomosis gastric bypass/minigastric bypass (OAGB/MGB) [5].

Weight loss, no matter how achieved, decreases the risk of ASCVD, cardiovascular events, and total mortality. Weight loss has beneficial effects on the main risk factors for ASCVD including elevated total and LDL-cholesterol (LDL-C), triglycerides, and decreased HDL-cholesterol (HDL-C) [6]. Bariatric surgery has beneficial effects on cardiovascular indices [7–9]. For instance, it has been shown that gastric bypass surgery improved all lipid profile parameters, although sleeve gastrectomy only improved HDL-C and triglyceride levels [10, 11]. It has also been recently demonstrated that sleeve gastrectomy causes an increase in HDL-C and that biliopancreatic diversion causes a significant decrease in total cholesterol, LDL-C, non-HDL-C, and LDL-C/non-HDL-C [12]. It has also been shown that bariatric surgery might prevent or slow atherogenesis in the early stages by breaking the vicious circle between inflammation and endothelial dysfunction [13]. Bariatric surgery also results in a decrease in pulse wave velocity (PWV), which might be used as an independent surrogate marker of ASCVD improvement [14].

Lipoprotein (a) (Lp(a)) is a cholesterol-rich LDL moiety that is covalently linked to a glycoprotein-apolipoprotein (a) ((apo (a)) by a disulfide bond [15]. Elevated plasma Lp(a) is widely accepted as a causal risk factor for myocardial infarction, atherothrombotic stroke, and calcified aortic stenosis [16–22]. Genetic findings strongly suggest that elevated plasma Lp(a), similarly to elevated LDL-C, is causally related to premature ASCVD and cardiovascular events, as well as mortality [23–26]. The accumulation of the LDL component in atherosclerotic plaque is regarded to be an important component of the atherogenic processes. Also, prothrombotic effects due to homology of apo (a) and plasminogen, as well as induction of a multilevel proinflammatory response mediated by oxidized phospholipid (OxPL), are supposed to be additional atherogenic mechanisms [27, 28]. The prothrombogenic and proinflammatory effects of Lp(a) have been proposed to promote plaque instability, resulting in plaque rupture and atherothrombotic events [29]. Overall, Lp(a) plasma levels are stable, although variants in the LPA gene determine 30–40% of the variance [30]. However, LPA gene expression may be increased by inflammation, while diseases like hypothyroidism and chronic kidney disease may affect Lp(a) removal.

Considering the profound metabolic changes that occur after bariatric surgery and its effect on proatherogenic lipoproteins [12], the aim of this meta-analysis was to evaluate whether bariatric surgery could change Lp(a) concentrations. So far, no meta-analysis has been performed to analyze this issue.

2. Methods

2.1. Search Strategy. This meta-analysis was performed based on the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines [31]. From inception to May 1st, 2021, PubMed, Scopus, Embase, and Web of Science were searched using the following keywords in titles and abstracts (also in combination with MESH terms): (“bariatric surgery” OR gastroplasty* OR “gastric bypass” OR “Roux-en-Y” OR “gastric band” OR “biliopancreatic diversion” OR gastrectomy* OR “duodenal switch” OR “gastrointestinal diversion” OR gastroenterostomy* OR “jejunoileal bypass” OR “obesity surgery” OR “weight loss surgery” OR “weight-loss surgery” OR “bariatric procedure” OR “sleeve surgery” OR “metabolic surgery”) AND (“lipoprotein (a)” OR “lipoprotein (a)” OR “Lp(a)”).

2.2. Study Selection. Only original peer-reviewed studies written in English were considered. All forms of bariatric surgery procedures (with or without supplemental medical therapies) which reported circulating Lp(a) levels before and after surgery were studied. The exclusion criteria were abstracts only, letters, case reports, comments, meta-analyses, duplicate studies, animal studies, reviews, non-English language papers, studies with no surgical intervention, and studies without outcomes.

2.3. Data Extraction. After deleting duplicate studies, two independent authors examined the titles and abstracts of the remaining papers for eligibility. The full texts of the eligible studies were collected. If two (or more) papers on the same research topic were published by the same organization and/or authors, the more recent study with a larger sample size was included. Any disagreements were resolved by authors’ discussion and consensus. The following information was extracted: (1) first author’s name, (2) year of publication, (3) type of surgery, (4) study design, (5) characteristics of the patients, (6) levels of Lp(a), and (7) duration of follow-up.

2.4. Quality Assessment. The Newcastle-Ottawa Scale (NOS) was applied to evaluate study quality in this meta-analysis [32]. Three features of each study were taken into account for this scale: (1) the selection of studied patients (4 items), (2) the comparability of studied populations (1 item), and (3) the ascertainment of exposure (3 items) in case-control studies or outcome of interest in cohort studies.

2.5. Quantitative Data Synthesis. This meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [33]. Information regarding sample size, means, and standard deviations from each group was extracted to calculate the standardized mean differences (SMDs). SMDs were applied because several different types of assays were used to determine plasma Lp(a) levels. Random effects meta-analysis was used to estimate the effect size. The heterogeneity of studies regarding treatment
| Study year                | Study design     | Baseline Lp(a) | Follow-up          | Treatment       | Control                  | Clinical outcome Lp(a)                                                                 | Patients                                                                 | No. of patients |
|--------------------------|------------------|----------------|--------------------|-----------------|--------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------|
| Ram et al., 2007 [38]    | Prospective study| 30.30 ± 3.65   | 3 months 12 months | SRVG            | —                        | Significant decrease in Lp(a) levels in both groups                                     | Women with obesity Men with obesity                                      | 14 11          |
| Williams et al., 2007 [39]| Prospective study| 137.61 ± 45.90 | 3 months 6 months 12 months | RYGB           | —                        | Significant decrease in Lp(a) levels                                                   | Patients with obesity                                                     | 121 103 85    |
| Morton and Boussard, 2009 [40]| Prospective study| 14.00 ± 3.65   | 12 months          | LRYGB           | —                        | Significant decrease in Lp(a) levels                                                  | Adolescents with obesity                                                 | 32             |
| Woodard et al., 2010 [41]| Prospective study| 32.20 ± 2.40  35.40 ± 8.20 | 12 months         | RYGB LAGB       | —                        | Unchanged                                                                              | Patients with obesity                                                     | 765 73         |
| To et al., 2012 [42]     | Retrospective study| 35.00 ± 36.00  | 6 months 12 months 24 months | LSG            | —                        | Significant decrease in Lp(a) levels at 12 months                                        | Patients with obesity                                                     | 52 39 5        |
| Berk et al., 2017 [43]   | Prospective study| 88.88 ± 189.62 | 3 months           | RYGB or gastric banding | Obese individuals without type 2 diabetes (dietary intervention) | Unchanged                                                                              | Patients with obesity without T2DM                                        | 26             |
| Gómez-Martín et al., 2017 [44]| Prospective study| 40.00 ± 39.00  43.00 ± 64.00 | 6 months 12 months | LRYGB SG        | Unchanged                                                            | Women matched for age and cardiovascular risk (diet and lifestyle modification) | Women with obesity                                                      | 20 20          |
| Lin et al., 2018 [45]    | Prospective study| 34.25 ± 59.03  34.25 ± 26.67 | 1 month 6 months | RYGB SG         | —                        | Significant decrease in Lp(a) levels at 1 month                                          | Premenopausal women                                                     | 27 35          |
| Carmona-Maurici et al., 2020 [46]| Prospective study| 258.17 ± 377.96 420.77 ± 462.56 | 6 months 12 months | LRYGB or SG    | —                        | Significant decrease in Lp(a) levels at 12 months in both groups                        | Patients with obesity without plaque                                          | 34 32          |
| Desprès et al., 2020 [47]| Prospective study| 69.50 ± 411.16 | 24 hours 5 days 6 months 12 months | Biliopancreatic diversion with duodenal switch (BPD-DS) | —                        | Significant increase in Lp(a) levels at 5 days                                           | Patients with obesity                                                     | 69             |
| Kruschitz et al., 2020 [48]| Clinical trial   | 56.40 ± 91.60 | 1 month 6 months 12 months | Laparoscopic one anastomosis gastric bypass | —                        | Significant decrease in Lp(a) levels                                                  | Patients with obesity, serum 25(OH)D concentrations of < 75 nmol/L          | 50 43 37       |
| Study year | Study design | Baseline Lp(a) | Follow-up | Treatment | Control | Clinical outcome Lp(a) | Patients | No. of patients |
|------------|--------------|----------------|-----------|-----------|---------|-----------------------|----------|----------------|
| Paredes et al., 2020 [49] | Retrospective study | 42.76 ± 126.82 | 12 months | SG | — | Significant decrease in Lp(a) levels | Patients without metabolic syndrome | 114 |
| Ho et al., 2021 [50] | Prospective study | 40.97 ± 155.40 | 6 months | RYGB or SG or omega loop bypass | Medical weight management | Significant increase in Lp(a) levels | Patients with obesity | 59 |

LRYGB: laparoscopic Roux-en-Y gastric bypass; LAGB: laparoscopic adjustable gastric banding; LSG: laparoscopic sleeve gastrectomy; SRVG: silastic ring vertical gastroplasty; RYGB: Roux-en-Y gastric bypass; SG: sleeve gastrectomy.
duration, study design, and the characteristics of the studied populations was determined using a random-effects model (owing to interstudy heterogeneity) and the generic inverse variance weighting approach [31]. When the outcome measures were reported as median and range (or 95% confidence interval (CI)), mean and SD values were computed by the approach described by Hozo et al. [34]. When only standard error of the mean (SEM) was reported, SD was computed using the following formula:

$$SD = SEM \times \sqrt{n},$$

where "n" represents the number of participants. To analyze the influence of each study on the overall effect size, a sensitivity analysis was done using the leave-one-out approach (i.e., deleting one study each time and repeating the analysis) [35, 36]. Statistical heterogeneity between the trials was evaluated using Cochran’s Q test and I² statistic as a measure of variability.

2.6. Metaregression. A metaregression analysis was performed to investigate the impact of changes in body mass index (BMI) and postsurgery follow-up duration with the estimated effect size of surgery on Lp(a) concentrations.

2.7. Publication Bias. To investigate the presence of publication bias, the funnel plot, Begg’s rank correlation, and Egger’s weighted regression tests were used. When funnel plot asymmetry was detected, potentially missing studies were inserted using the “trim and fill” approach. In case of a significant result, the number of potentially missing studies needed to render the p value nonsignificant was calculated by the “fail-safe N” approach as another indicator of publication bias [37].

3. Results

A thorough database search identified 99 published papers, 49 of which were directly related to the topic of this meta-analysis. After careful consideration, 36 studies were excluded: 10 studies were reviews, 10 studies did not meet the inclusion criteria, 15 studies did not report sufficient data, and one was a study protocol only. Therefore, 13 studies which evaluated the levels of Lp(a) before and after bariatric surgery were included (Table 1). The study selection process is shown in Figure 1. Assessment of risk of bias in the included studies is summarized in Table 2. Risk assessments for all studies were deemed to have high risk of bias.

3.1. Quality Assessment of the Included Studies. Because most of the studies did not have a control group, they were not evaluated for selection of controls, definition of controls, comparability, the same method of ascertainment, and non-response rate. However, all studies which were included met the ascertainment of exposure criteria. Table 2 shows the details of quality assessment.

3.2. Methods for Measuring Lp(a). In most of the included studies, serum Lp(a) was assessed using the enzyme-linked immunosorbent assay (ELISA) [46]. One study used
standard colorimetric methods using the Architect ci8200 analyzer (Abbot Diagnostics, Berkshire, UK) [44]. One study used particle-enhanced immunoturbidimetry (Diagnostic System GmbH, Holzheim, Germany) [43] while another used the turbidimetric assay using the Tina-quant Lipoprotein (a) Gen.2 system (Cobas Integra 400/800, Roche Diagnostics, Mannheim, Germany) [47]. Another study assessed Lp(a) by chemiluminescent immunoassays [50], and one study used the Cobas Mira Plus (Roche Diagnostics) analyzer [38]. In seven studies, the method was not specifically mentioned [39–42, 45, 48, 49].

3.3. Effects of Bariatric Surgery on Circulating Concentrations of Lp(a). Meta-analysis of 13 studies including 1551 subjects showed a significant decrease of circulating Lp(a) after bariatric surgery (SMD: -0.438, 95% CI: -0.702, -0.174, p < 0.001, I²: 94.05%) (Figure 2(a)). The reduction in circulating Lp(a) was robust in the leave-one-out sensitivity analysis (Figure 2(b)).

3.4. Effects of Bariatric Surgery on BMI and Circulating Concentrations of LDL-C, HDL-C, and oxLDL. BMI in 12 studies including 1530 subjects showed a significant increase of HDL-C after bariatric surgery (WMD: 7.390 mg/dL, 95% CI: 5.733, 9.046, p < 0.001, I²: 94.86%) as well as significant reduction in LDL-C levels (WMD: -14.166 mg/dL, 95% CI: -21.831, -6.502, p < 0.001, I²: 92.96%) (Figures 3(c) and 3(d)).

3.5. Metaregression. To investigate the impact of potential confounders on the Lp(a) lowering effect of bariatric surgery, random-effects metaregression was used. The results did not indicate any significant association between the changes in Lp(a) and percentage of BMI change (slope: 0.019; 95% CI: -0.037, 0.076; p = 0.507) or duration of follow-up (slope: -0.036; 95% CI: -0.112, 0.040; p = 0.355). Figure 4 is shown.

3.6. Publication Bias. Figure 5 shows a funnel plot to evaluate publication bias across studies included in the meta-analysis. Egger’s linear regression test (intercept = 2.935, standard error = 1.62; 95% CI = -0.498, 6.370, t = 1.803, df = 17, two-tailed p = 0.089) and Begg’s rank correlation test (Kendall’s Tau with continuity correction = -0.257, z = 1.57, two-tailed p = 0.115) did not indicate the presence of publication bias in this meta-analysis of bariatric surgery effects on circulating Lp(a). Trim-and-fill analysis indicated that among all papers included in this meta-analysis, there could be five missing studies. The “fail-safe N” test showed that 842 missing studies were required to reduce the effect size to a nonsignificant (p < 0.001) value. Statistical heterogeneity was observed as Cochran’s Q-test and I² (p < 0.05 and I² > 50%, respectively).
This meta-analysis showed a significant reduction in circulating Lp(a) levels after bariatric surgery. Several meta-analyses have analyzed these effects particularly in patients with type 2 diabetes. Favourable effects have been shown on serum triglycerides, total cholesterol, LDL-C, and HDL-C concentrations following bariatric surgery depending on its type and the anatomic alterations unique to each procedure [51–54].

Although an elevated Lp(a) level is independently associated with the incidence of cardiovascular events in the general
| Study name                        | Difference in means | Standard error | Variance | Lower limit | Upper limit | Z-value | p-value | Variance | Lower limit | Upper limit | Z-value | p-value |
|----------------------------------|---------------------|----------------|----------|-------------|-------------|---------|---------|----------|-------------|-------------|---------|---------|
| Ho et al, 2021                   | -14.380             | 0.734          | 0.539    | -15.818     | -12.942     | -19.594 | 0.000   |          |             |             |         |         |
| Paredes et al, 2020a             | -14.200             | 0.414          | 0.172    | -15.012     | -13.388     | -34.280 | 0.000   |          |             |             |         |         |
| Paredes et al, 2020b             | -13.400             | 0.479          | 0.229    | -14.338     | -12.462     | -27.987 | 0.000   |          |             |             |         |         |
| Kruschitz et al, 2020            | -15.600             | 0.671          | 0.448    | -16.912     | -14.288     | -23.297 | 0.000   |          |             |             |         |         |
| Després et al, 2020              | -18.800             | 0.758          | 0.574    | -20.286     | -17.314     | -24.804 | 0.000   |          |             |             |         |         |
| Carmona maurici et al, 2020a     | -15.500             | 1.465          | 2.147    | -18.372     | -12.628     | -10.578 | 0.000   |          |             |             |         |         |
| Carmona maurici et al, 2020b     | -14.200             | 1.314          | 1.728    | -16.776     | -11.624     | -10.803 | 0.000   |          |             |             |         |         |
| Gómez-martín et al, 2018a        | -15.900             | 1.237          | 1.531    | -18.325     | -13.475     | -12.852 | 0.000   |          |             |             |         |         |
| Gómez-martín et al, 2018b        | -12.400             | 0.883          | 0.781    | -14.132     | -10.668     | -14.036 | 0.000   |          |             |             |         |         |
| Berk et al, 2017                 | -6.300              | 0.659          | 0.434    | -7.592      | -5.008      | -9.560  | 0.000   |          |             |             |         |         |
| To et al, 2012                   | -13.000             | 3.821          | 14.600   | -20.489     | -5.511      | -3.402  | 0.001   |          |             |             |         |         |
| Woodard et al, 2010a             | -16.000             | 0.013          | 0.000    | -16.026     | -15.974     | -227.380| 0.000   |          |             |             |         |         |
| Woodard et al, 2010b             | -9.100              | 1.000          | 0.010    | -9.296      | -8.904      | -91.000 | 0.000   |          |             |             |         |         |
| Williams et al, 2007             | -16.000             | 0.314          | 0.314    | -16.616     | -15.384     | -50.902 | 0.000   |          |             |             |         |         |
| Ram et al, 2007a                 | -15.300             | 0.989          | 0.978    | -17.328     | -13.362     | -15.472 | 0.000   |          |             |             |         |         |
| Ram et al, 2007b                 | -15.500             | 1.538          | 2.365    | -18.514     | -12.486     | -10.080 | 0.000   |          |             |             |         |         |
|                                  | -14.101             | 1.126          | 1.267    | -16.308     | -11.895     | -12.526 | 0.000   |          |             |             |         |         |

**Meta analysis**

(a) BMI

| Study name          | Difference in means | Standard error | Variance | Lower limit | Upper limit | Z-value | p-value |
|---------------------|---------------------|----------------|----------|-------------|-------------|---------|---------|
| Ho et al, 2021      | -1.550              | 5.425          | 29.436   | 12.184      | 9.084       | -0.286  | 0.775   |
| Gómez-martín et al, 2018a | -10.930          | 0.567          | 0.321    | -12.041     | -9.819      | -19.282 | 0.000   |
| Gómez-martín et al, 2018b | -4.540            | 1.003          | 1.007    | -6.507      | -2.573      | -4.525  | 0.000   |
|                     | -6.717              | 2.906          | 8.447    | -12.413     | -1.021      | -2.311  | 0.021   |

(b) OxLDL

**Figure 3: Continued.**
Figure 3: Effects of bariatric surgery on BMI and circulating concentrations of LDL-C, HDL-C, and oxLDL.
population and it is an established predictor of cardiovascular events in patients with ASCVD [55, 56], the possibilities of decreasing elevated Lp(a) are still quite limited [57–63]. Unlike LDL-C and triglycerides, Lp(a) is relatively refractory to diet [64], lifestyle changes [65], and most drug interventions. Among medications, statins could increase plasma Lp(a) levels [66]. However, a decrease in Lp(a) concentrations can be achieved to a certain extent with niacin [67] which is not widely available. Mipomersen, an antisense oligonucleotide against apolipoprotein B [68–71], had the potential benefit to reduce Lp(a) by 20%, but this drug is approved by the FDA only as an orphan drug for homozygous familial hypercholesterolemia [72]. Currently, the only drugs on the market which can decrease Lp(a) significantly (about 25%) are proprotein subtilisin/kexin type 9 (PCSK9) inhibitors—alirocumab and evolocumab [73, 74]. A post hoc analysis of the Odyssey outcomes study suggested that a part of the benefits of alirocumab in reducing ASCVD events could be ascribed to its Lp(a) lowering effects, mainly on a subgroup of patients with high Lp(a) levels that had a recent myocardial infarction [75]. However, decreasing Lp(a) is not commonly accepted as an indication for use of PCSK9 inhibitors. Recently, data from a phase 2b trial with pelacarsen (an apo (a) antisense oligonucleotide) have attracted significant interest [76].

In this meta-analysis, bariatric surgery was shown to reduce Lp(a) levels despite the heterogeneity of the included studies. It has to be stressed that there was no association between changes in Lp(a) levels and weight loss or follow-up duration. An important question is: what mechanisms may cause these findings? One possibility is the consistent reduction in the obesity proinflammatory state indicated by lower levels of C reactive protein [77] and interleukin-6.

**Figure 4:** Random-effects metaregression for assessing the effect of % BMI change (a) and follow-up duration (b).

**Figure 5:** Funnel plot detailing publication bias in the studies reporting the effect of bariatric surgery on Lp(a).
(IL-6) after bariatric surgery [78]. Also, the LPA gene promoter contains IL-6-responsive elements consistent with Lp(a) acute phase response of apo(a) [79]. However, further studies are necessary to prove this hypothesis.

Previous findings on the reduction of LDL-C and atherogenic dyslipidemia [10–12] and Lp(a) as shown in this meta-analysis may explain the beneficial effects of bariatric surgery on individuals at high risk of ASCVD and mortality. However, this needs to be verified [3]. Moreover, it has been estimated that the magnitude of reduction required to achieve an ASCVD benefit is roughly 55 mg/dL [80]. Therefore, it has to be further explored whether Lp(a) reduction with bariatric surgery is of clinical relevance.

One of the limitations of this study was that the methods for measuring Lp(a) concentrations in some studies were different, and this might explain the heterogeneity in our findings. However, using SMD as the summary statistic in this meta-analysis could reduce this error. Indeed, because of the structural properties of Lp(a), none of the available commercial assays for Lp(a) quantification is 100% inherently isoform-sensitive [81]. We were also not able to establish the contribution of either apo(a) isoform size or variants in LPA gene [82]. Besides, some studies had no control group; some had small groups of patients or were not randomized. However, the results were still robust after the leave-one-out sensitivity analysis. Lp(a) has very little variability in different measures in individuals with stable health conditions [83]. We were also not able to evaluate the absolute reductions in Lp(a) and whether the effects were greater in patients with elevated Lp(a) levels. Finally, we were also unable to determine the specific impact of different bariatric surgery techniques, which may produce significantly stronger or weaker responses.

5. Conclusion

Obesity is associated with an increased ASCVD risk, and this association is consistent between sexes and across different parts of the world. This meta-analysis suggests that bariatric surgery significantly decreases circulating Lp(a) concentrations. Since elevated Lp(a) is independently associated with ASCVD, the results of this study may have clinical implications for severely obese individuals with high cardiovascular risk. However, it is worth mentioning that the estimates of the magnitude reduction required to achieve an ASCVD benefit are roughly 55 mg/dL [80].

Data Availability

There is no primary data associated with this study.

Conflicts of Interest

RDS reports receiving the following: consulting fees and lecture fees from Abbott, Amgen, Astra Zeneca, Aché, EMS, Getz Pharma, Libbs, Merck, Merck Sharp & Dohme, PTC Therapeutics, Novo Nordisk, Novartis, and Sanofi-Regeneron Pharmaceuticals outside this work. RDS has received honoraria related to consulting, speaker activities, and/or research from Abbott, Amgen, Astra Zeneca, Aché, Esperion, EMS, Hypera, Getz Pharma, Kowa, Libbs, PTC Pharmaceuticals, Pfizer, Medley, Merck, MSD, Novo-Nordisk, Novartis, and Sanofi.

Acknowledgments

Tannaz Jamialahmadi was supported by the Wael-Almahmeed & IAS Research Training Grant. RDS is a recipient of a research scholarship from Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico, Brazil (CNPq) #303734/2018-3.

References

[1] S. Kim, M. W. Lee, T. S. Kim et al., “Intracoronary dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular imaging with a clinical dose of indocyanine green for the assessment of high-risk plaques and stent-associated inflammation in a beating coronary artery,” European Heart Journal, vol. 37, no. 37, pp. 2833–2844, 2016.
[2] H. Dai, T. A. Alsalhe, N. Chalghaf, M. Riccò, N. L. Bragazzi, and J. Wu, “The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: an analysis of the Global Burden of Disease Study,” PLoS Medicine, vol. 17, no. 7, article e1003198, 2020.
[3] N. L. Syn, D. E. Cummings, L. Z. Wang et al., “Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants,” Lancet, vol. 397, no. 10287, pp. 1830–1841, 2021.
[4] J. P. Després, A. C. Carpentier, A. Thernof, I. J. Neeland, and P. Poirier, “Management of obesity in cardiovascular practice,” Journal of the American College of Cardiology, vol. 78, no. 5, pp. 513–531, 2021.
[5] C. Coelho, J. Crane, R. Agius, and B. McGowan, “The bariatric-metabolic physician’s role in managing clinically severe obesity,” Current Obesity Reports, vol. 10, no. 3, pp. 263–273, 2021.
[6] F. L. Visseren, F. Mach, Y. M. Smulders et al., “2021 ESC guidelines on cardiovascular disease prevention in clinical practice,” European Heart Journal, vol. 42, no. 34, pp. 3227–3337, 2021.
[7] T. Jamialahmadi, Ž. Reiner, M. Alidadi et al., “The effect of bariatric surgery on circulating levels of oxidized low-density lipoproteins is apparently independent of changes in body mass index: a systematic review and meta-analysis,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 4136071, 13 pages, 2021.
[8] T. Jamialahmadi, M. Alidadi, S. L. Atkin et al., “Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis,” Journal of Clinical Medicine, vol. 11, no. 14, p. 4054, 2022.
[9] N. Nabavi, A. Ghodsi, R. Rostami et al., “Impact of bariatric surgery on carotid intima-media thickness in patients with
morbid obesity: a prospective study and review of the literature,” *Obesity Surgery*, vol. 32, no. 5, pp. 1563–1569, 2022.

[10] K. A. Carswell, A. P. Belgaumkar, S. A. Amiel, and A. G. Patel, “A systematic review and meta-analysis of the effect of gastric bypass surgery on plasma lipid levels,” *Obesity Surgery*, vol. 26, no. 4, pp. 843–855, 2016.

[11] L. A. Garay, M. I. N. García, N. M. T. Pérez, and J. L. V. Rojas, “Medium/long term evaluation of lipid profile after bariatric surgery (gastric bypass versus sleeve gastrectomy),” *Endocrinología, Diabetes y Nutrición*, vol. 68, no. 6, pp. 372–380, 2021.

[12] E. G. Arnáiz, M. D. Ballesteros Pomar, L. G. Roza et al., “Evaluation of lipoprotein profile and residual risk three years after bariatric surgery,” *Obesity Surgery*, vol. 31, no. 9, pp. 4033–4044, 2021.

[13] J. Carmona-Maurici, E. Cuello, D. Ricart-Jané et al., “Effect of bariatric surgery on inflammation and endothelial dysfunction as processes underlying subclinical atherosclerosis in morbid obesity,” *Surgery for Obesity and Related Diseases*, vol. 16, no. 12, pp. 1961–1970, 2020.

[14] T. Jamialahmadi, Ž. Reiner, M. Alidadi et al., “Impact of bariatric surgery on pulse wave velocity as a measure of arterial stiffness: a systematic review and meta-analysis,” *Obesity Surgery*, vol. 31, no. 10, pp. 4461–4469, 2021.

[15] Ž. Reiner, “Can Lp (A) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?,” *Current Atherosclerosis Reports*, vol. 21, no. 4, pp. 1–8, 2019.

[16] F. Kronenberg, M. F. Kronenberg, S. Kiechl et al., “Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis,” *Circulation*, vol. 100, no. 11, pp. 1154–1160, 1999.

[17] B. G. Nordestgaard, M. J. Chapman, K. Ray et al., “Lipoprotein (a) as a cardiovascular risk factor: current status,” *European Heart Journal*, vol. 31, no. 23, pp. 2844–2853, 2010.

[18] J. Boras, S. Ljubic, N. Car et al., “Lipoprotein (a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up,” *Wiener klinische Wochenschrift*, vol. 122, no. 5–6, pp. 159–164, 2010.

[19] Ž. Reiner, A. L. Catapano, G. De Backer et al., “ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS),” *European Heart Journal*, vol. 32, no. 14, pp. 1769–1818, 2011.

[20] G. Thanassoulis, “Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis,” *Journal of Lipid Research*, vol. 57, no. 6, pp. 917–924, 2016.

[21] K. L. Ellis, M. B. Boffa, A. Sahebkar, M. L. Koschinsky, and G. F. Watts, “The renaissance of lipoprotein(a): brave new world for preventive cardiology?,” *Progress in Lipid Research*, vol. 68, pp. 57–82, 2017.

[22] G. Ferretti, T. Bacchetti, T. P. Johnston, M. Banach, M. Pirro, and A. Sahebkar, “Lipoprotein(a): a missing culprit in the management of athero-thrombosis?,” *Journal of Cellular Physiology*, vol. 233, no. 4, pp. 2966–2981, 2018.

[23] P. R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, and B. G. Nordestgaard, “Genetically elevated lipoprotein (a) and increased risk of myocardial infarction,” *Journal of the American Medical Association*, vol. 301, no. 22, pp. 2331–2339, 2009.

[24] S. M. Zekavat, S. Ruotsalainen, R. E. Handsaker et al., “Deep coverage whole genome sequences and plasma lipoprotein (a) in individuals of European and African ancestors,” *Nature Communications*, vol. 9, no. 1, pp. 1–14, 2018.

[25] A. Langsted, B. G. Nordestgaard, and P. R. Kamstrup, “Low lipoprotein (a) levels and risk of disease in a large, contemporary, general population study,” *European Heart Journal*, vol. 42, no. 12, pp. 1147–1156, 2021.

[26] D. F. Gudbjartsson, T. Thorgerisson, P. Sulem et al., “Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes,” *Journal of the American College of Cardiology*, vol. 74, no. 24, pp. 2982–2994, 2019.

[27] Y. Kaiser, M. Daghem, E. Tzolos et al., “Association of lipoprotein (a) with atherosclerotic plaque progression,” *Journal of the American College of Cardiology*, vol. 79, no. 3, pp. 223–232, 2022.

[28] B. Gencer, F. Kronenberg, E. S. Stroes, and F. Mach, “Lipoprotein (a): the revenant,” *European Heart Journal*, vol. 38, no. 20, pp. 1553–1560, 2017.

[29] P. J. Nestel, E. H. Barnes, A. M. Tonkin et al., “Plasma lipoprotein (a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 12, pp. 2902–2908, 2013.

[30] F. Kronenberg and G. Utermann, “Lipoprotein(a): resurrected with genetics,” *Journal of Internal Medicine*, vol. 273, no. 1, pp. 6–30, 2013.

[31] A. J. Sutton, K. R. Abrams, D. R. Jones, D. R. Jones, T. A. Sheldon, and F. Song, “Methods for meta-analysis in medical research,” *Wiley Chichester*, vol. 348, 2000.

[32] G. A. Wells, B. Shea, D. O’Connell et al., “The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses,” 2000.

[33] M. Borenstein, L. Hedges, J. Higgins, and H. Rothstein, *Comprehensive Meta-Analysis, Version 2 Biostat*, Englewood NJ, 2005.

[34] S. P. Hozo, B. Djulbegovic, and I. Hozo, “Estimating the mean and variance from the median, range, and the size of a sample,” *BMC Medical Research Methodology*, vol. 5, no. 1, pp. 1–10, 2005.

[35] M. Banach, C. Serban, A. Sahebkar et al., “Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies,” *BMC Medicine*, vol. 13, no. 1, pp. 1–21, 2015.

[36] M. Banach, C. Serban, S. Ursoniu et al., “Statin therapy and plasma coenzyme Q10 concentrations—a systematic review and meta-analysis of placebo-controlled trials,” *Pharmacological Research*, vol. 99, pp. 329–336, 2015.

[37] S. Duval and R. Tweedie, “Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,” *Biometrics*, vol. 56, no. 2, pp. 455–463, 2000.

[38] E. Ram, T. Visha, A. Magazanik et al., “Changes in blood lipid levels following silastic ring vertical gastroplasty,” *Obesity Surgery*, vol. 17, no. 10, pp. 1292–1296, 2007.

[39] D. B. Williams, J. C. Hagedorn, E. H. Lawson et al., “Changes in blood lipid levels following silastic ring vertical gastroplasty,” *Obesity Surgery*, vol. 3, no. 1, pp. 8–13, 2007.

[40] J. Morton and T. Boussard, “Gastric bypass reduces cardiac risk factors in the adolescent morbidly obese,” *Obesity Surgery*, vol. 19, no. 8, article 984, 2009.
[41] G. A. Woodard, J. Peraza, S. Bravo, L. Topolsky, T. Hernandez-Boussard, and J. M. Morton, “One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding,” Obesity Surgery, vol. 20, no. 5, pp. 578–582, 2010.

[42] V. T. To, T. P. Buttell, R. Lang, K. Piotrowski, and K. G. Parhofer, “Changes in body weight, glucose homeostasis, lipid profiles, and metabolic syndrome after restrictive bariatric surgery,” Experimental and Clinical Endocrinology & Diabetes, vol. 120, no. 9, pp. 547–552, 2012.

[43] K. A. Berk, R. Yahya, A. J. M. Verhoeven et al., “Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes,” Diabetologia, vol. 60, no. 6, pp. 989–997, 2017.

[44] J. M. Gómez-Martin, J. A. Balsa, E. Aracil et al., “Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy,” Lipids in Health and Disease, vol. 17, no. 1, pp. 1–9, 2018.

[45] B. X. Lin, M. C. Weiss, M. Parikh, J. S. Berger, E. A. Fisher, and S. P. Heffron, “Changes in lipoprotein(a) following bariatric surgery,” American Heart Journal, vol. 197, pp. 175-176, 2018.

[46] J. Carmona-Maurici, N. Amigó, E. Cuello et al., “Bariatric surgery decreases oxidative stress and protein glycosylation in patients with morbid obesity,” European Journal of Clinical Investigation, vol. 50, no. 11, article e13320, 2020.

[47] A. A. Després, M. E. Piché, A. Auclair et al., “Acute and chronic impact of biliopancreatic diversion with duodenal switch surgery on plasma lipoprotein(a) levels in patients with severe obesity,” Obesity Surgery, vol. 30, no. 10, pp. 3714–3720, 2020.

[48] R. Krszczitz, M. Wakolbinger, K. Schindler et al., “Effect of one-anastomosis gastric bypass on cardiovascular risk factors in patients with vitamin D deficiency and morbid obesity: a secondary analysis,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 30, no. 12, pp. 2379–2388, 2020.

[49] S. Paredes, M. Alves, M. L. Pereira, O. Marques, and L. Ribeiro, “Lipoprotein(a) change after sleeve gastrectomy is affected by the presence of metabolic syndrome,” Obesity Surgery, vol. 30, no. 2, pp. 545–552, 2020.

[50] J. H. Ho, S. Adam, Y. Liu et al., “Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a),” Journal of Clinical Lipidology, vol. 15, no. 2, pp. 320–331, 2021.

[51] D.-f. Liu, Z.-y. Ma, C.-s. Zhang et al., “The effects of bariatric surgery on dyslipidemia and insulin resistance in overweight patients with or without type 2 diabetes: a systematic review and network meta-analysis,” Surgery for Obesity and Related Diseases, vol. 17, no. 9, pp. 1655–1672, 2021.

[52] B. Hasan, T. Nayfeh, M. Alzuabi et al., “Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 12, pp. 3695–3703, 2020.

[53] L. Ding, Y. Fan, H. Li et al., “Comparative effectiveness of bariatric surgeries in patients with obesity and type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials,” Obesity Reviews, vol. 21, no. 8, article e13030, 2020.

[54] S. P. Heffron, A. Parikh, A. Volodarskiy et al., “Changes in lipid profile of obese patients following contemporary bariatric surgery: a meta-analysis,” The American Journal of Medicine, vol. 129, no. 9, pp. 952–959, 2016.

[55] P. Willeit, P. M. Ridker, P. J. Nestel et al., “Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials,” The Lancet, vol. 392, no. 10155, pp. 1311–1320, 2018.

[56] Z. Wang, X. Zhai, M. Xue, W. Cheng, and H. Hu, “Effects of fat-to-sugar ratio in excess dietary energy on lipid abnormalities: a 7-month prospective feeding study in adult cynomolagus monkeys,” Lipids in Health and Disease, vol. 18, no. 1, pp. 1–9, 2019.

[57] G. Ferretti, T. Bacchetti, L. E. Simental-Mendía, Z. Reiner, M. Banach, and A. Sahebkar, “Raloxifene lowers plasma lipoprotein (a) concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials,” Cardiovascular Drugs and Therapy, vol. 31, no. 2, pp. 197–208, 2017.

[58] K. Kotani, A. Sahebkar, C. Serban et al., “Tibolone decreases lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients,” Atherosclerosis, vol. 242, no. 1, pp. 87–96, 2015.

[59] A. A. Momtazi-Borjomi, N. Katsiki, M. Pirro, M. Banach, K. A. Rasadi, and A. Sahebkar, “Dietary natural products as emerging lipoprotein(a)-lowering agents,” Journal of Cellular Physiology, vol. 234, no. 8, pp. 12581–12594, 2019.

[60] A. Sahebkar, N. Katsiki, N. Ward, and Z. Reiner, “Flaxseed supplementation reduces plasma lipoprotein (A) levels: a meta-analysis,” Alternative Therapies in Health and Medicine, vol. 27, no. 3, pp. 50–53, 2021.

[61] A. Sahebkar, M. C. Serban, P. Pensom et al., “The effects of tamoxifen on plasma lipoprotein (a) concentrations: systematic review and meta-analysis,” Drugs, vol. 77, no. 11, pp. 1187–1197, 2017.

[62] A. Sahebkar, L. E. Simental-Mendía, C. Stefanutti, and M. Pirro, “Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis,” Pharmacological Research, vol. 105, pp. 198–209, 2016.

[63] M. C. Serban, A. Sahebkar, D. P. Mikhailidis et al., “Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials,” Scientific Reports, vol. 6, no. 1, 2016.

[64] F. Grundler, D. Plonné, R. Mesnage et al., “Long-term fasting improves lipoprotein-associated atherogenic risk in humans,” European Journal of Nutrition, vol. 60, no. 7, pp. 4031–4044, 2021.

[65] B. Enkhmaa, K. S. Petersen, P. M. Kris-Etherton, and L. Berglund, “Diet and Lp (a): does dietary change modify residual cardiovascular risk conferred by Lp (a)?,” Nutrients, vol. 12, no. 7, p. 2024, 2020.

[66] S. Tsimikas, P. L. Gordts, C. Nora, C. Yeang, and J. L. Witztum, “Statin therapy increases lipoprotein (a) levels,” European Heart Journal, vol. 41, no. 24, pp. 2275–2284, 2020.

[67] A. Sahebkar, Z. Reiner, L. E. Simental-Mendía, G. Ferretti, and A. F. Cicero, “Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials,” Metabolism, vol. 65, no. 11, pp. 1664–1678, 2016.
antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein (a) in various populations with hypercholesterolemia: results of 4 phase III trials,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 35, no. 3, pp. 689–699, 2015.

[69] A. Sahebkar and G. F. Watts, “New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidemias: what can the clinician expect,” *Cardiovascular Drugs and Therapy*, vol. 27, no. 6, pp. 559–567, 2013.

[70] A. Sahebkar and G. F. Watts, “New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes,” *Clinical Therapeutics*, vol. 35, no. 8, pp. 1082–1098, 2013.

[71] C. Macchi, C. Sirtori, A. Corsini, R. Santos, G. Watts, and M. Ruscica, “A new dawn for managing dyslipidemias: the era of RNA-based therapies,” *Pharmacological Research*, vol. 150, article 104413, 2019.

[72] F. Fogacci, N. Ferri, P. P. Toth, M. Ruscica, A. Corsini, and A. F. Cicero, “Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials,” *Drugs*, vol. 79, no. 7, pp. 751–766, 2019.

[73] G. G. Schwartz, M. Szarek, V. A. Bittner et al., “Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol,” *Journal of the American College of Cardiology*, vol. 78, no. 5, pp. 421–433, 2021.

[74] P. P. Toth, S. R. Jones, M. L. Monsalvo, M. Elliott-Davey, J. A. G. López, and M. Banach, “Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein (a): a pooled analysis of phase 2 and phase 3 studies,” *Journal of the American Heart Association*, vol. 9, no. 5, article e014129, 2020.

[75] M. Szarek, V. A. Bittner, P. Aylward et al., “Lipoprotein (a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial,” *European Heart Journal*, vol. 41, no. 44, pp. 4245–4255, 2020.

[76] S. Tsimikas, E. Karwatowska-Prokopczuk, I. Gouni-Berthold et al., “Lipoprotein (a) reduction in persons with cardiovascular disease,” *New England Journal of Medicine*, vol. 382, no. 3, pp. 244–255, 2020.

[77] G. Reyes-Soffer and M. Westerterp, “Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation,” *Pharmacological Research*, vol. 169, article 105689, 2021.

[81] S. R. Rao, “Inflammatory markers and bariatric surgery: a meta-analysis,” *Inflammation Research*, vol. 61, no. 8, pp. 789–807, 2012.

[82] D. P. Wade, J. G. Clarke, G. E. Lindahl et al., “5′ control regions of the apolipoprotein (a) gene and members of the related plasminogen gene family,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 90, no. 4, pp. 1369–1373, 1993.

[80] C. M. Madsen, P. R. Kamstrup, A. Langsted, A. Varbo, and B. G. Nordestgaard, “Lipoprotein (a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 40, no. 1, pp. 255–266, 2020.

[81] S. M. Marcovina and J. J. Albers, “Lipoprotein (a) measurements for clinical application,” *Journal of Lipid Research*, vol. 57, no. 4, pp. 526–537, 2016.